Antineoplaston therapy plus radiation for brainstem glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding antineoplaston therapy (a substance that may slow cancer cell growth) to standard radiation helps people with a type of brain tumor called diffuse intrinsic pontine glioma (DIPG). It aims to see if the combination improves outcomes compared to radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 3 years old.
- You must have a confirmed diagnosis of diffuse intrinsic pontine glioma (DIPG), usually based on MRI findings. If the tumor involves less than half of the pons (a part of the brainstem), a biopsy must show a high-grade glioma.
- If you are between 3 and 21 years old, you must have had symptoms for less than 6 months and have at least two of these: cranial nerve problems, weakness on one side of the body, or difficulty with coordination.
- You must not have had any prior treatment for this tumor (except a biopsy or a shunt for fluid buildup).
- You must be generally healthy, with adequate blood counts, kidney and liver function, and no uncontrolled infections or other serious illnesses.
- If you are of childbearing potential, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether the experimental antineoplaston treatment affects the heart's electrical activity in people with a specific type of brain tumor called diffuse intrinsic brainstem glioma. It aims to ensure the treatment is safe for your heart, which is important for overall health during therapy.
This trial tests whether adding sonodynamic therapy (a treatment that uses sound waves to activate a drug) before standard radiation and chemotherapy can help people with a type of brainstem glioma called DIPG. The goal is to see if this combination improves survival.
This trial compares two types of radiation therapy for children with diffuse intrinsic pontine glioma (DIPG), a rare brain tumor. It aims to see which treatment may be more effective while helping you understand your options.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial tests a special form of radiation therapy for older or frail adults with a type of brain tumor called glioma. The radiation is placed directly in the area where the tumor was removed during surgery, which may help prevent the tumor from growing back.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Hear when a new Brain Stem Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.